1 DNA Way
South San Francisco
About Genentech, Inc.
Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.
On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.
Connect with us via Social Media:
CEO: Ian T. Clark
CEO: Ed Harrington
Chief Medical Officer: Sandra J. Horning, MD
Chief Compliance Officer: Frederick C. Kentz, III
Please click here for clinical trial information.
Living 10 Years in the Future
971 articles with Genentech, Inc.
Genentech announced today that the FDA has accepted the company’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of Rituxan (rituximab) .
The study assessed two doses of RG7716 versus ranibizumab standard of care given as monthly intravitreal injections.
Genentech said the Phase III combination therapy improved progression-free survival by 26 percent in mRCC patients whose disease expressed a PD-L1 protein.
The trial will assess the efficacy, safety, and pharmacokinetics of immunotherapy combination in HR+, HER2- metastatic breast cancer.
2017 was the second-best year for FDA approvals since 1996.
FDA Approves Genentech’s Perjeta (pertuzumab) for Adjuvant Treatment of Specific Type of Early Breast Cancer
Genentech announced the FDA has approved Perjeta (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen).
The fact that Roche has separate R&D units has been the topic of second-guessing on the part of observers and analysts.
A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal.
A look at the latest batch of FDA approvals this year.
12/12/2017A look at what three ex-Genentech employees have accomplished at Denali so far.
Asthma Intervention: Novel Impedance-Based Assay Monitors the Contraction and Relaxation of Smooth Muscle Cells and Fibroblasts in Real-Time
Contraction and relaxation of smooth muscle cells and fibroblasts within the bronchial airways dramatically affects airflow, and being able to modulate these processes is critical for treating asthma and allergic responses.
12/12/2017A look at some of the exciting data clinicians and investors got to feast on from ASH.
At the ASH meeting in Atlanta this morning, AbbVie and Genentech unveiled stellar results of its Phase III combination trial of Venclexta and Rituxan to treat patients with relapsed or refractory CLL.
Genentech’s HEMLIBRA (emicizumab-kxwh) Continued to Substantially Reduce Bleeds in People With Hemophilia A With Inhibitors
These data include longer-term results from the pivotal HAVEN 1 and HAVEN 2 studies in people with hemophilia A with inhibitors to factor VIII, showing once-weekly subcutaneous HEMLIBRA prophylaxis demonstrated superior efficacy compared to prior treatment with bypassing agents (BPAs) as prophylaxis or on-demand.
TECENTRIQ and Avastin showed improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1.
These data led to FDA Breakthrough Therapy and EMA PRIME (PRIority MEdicines) designations.
One of the most important points about Hemlibra’s approval, beyond its significant efficacy is the positive impact it will have one the quality of life for these hemophilia patients.
Patients who received Tecentriq and Avastin in addition to standard chemo showed a 38 percent reduction in the risk of the disease getting worse or death.
Genentech's HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds in Phase III Study in Hemophilia A
At this interim analysis after a median of 17 weeks of treatment, HEMLIBRA prophylaxis showed a clinically meaningful control of bleeding.
Avastin was previously granted provisional approval in this setting under the FDA's accelerated approval program.